Targeted gene panels are used to search for mutations in multiple DNA regions at the same time. Targeted panels are specific to the regions of the genome known to be associated with a specific disease or phenotype.
Addressing the antibody reproducibility crisis: A panel discussion with key scientific leaders Reproducibility and antibody validation standards are two significant challenges f...
EVENT DETAILS:DATE: May 16, 2017TIME: 9:00am PT, Noon ETThermo Fisher Scientific is proud to present the SyncD3 webinar series. As a thought-leader in science our first commit...
DATE: May 9, 2017TIME: 8:00am PT, 11:00am ETHearing loss is the most common sensory defect in humans. It affects 360 million people worldwide and by 2020, that number is predi...
DATE: April 26, 2017TIME: 9:00AM PT, 12:00PM ETBiopsies from non-small cell lung cancer (NSCLC) and colorectal adenocarcinoma generally produce small, heterogeneous samples with li...
DATE: April 20th, 2017TIME: 10:00AM SGT, 11:00AM KST, 12:00PM AEST, 2:00PM NZSTWith increasing breadth and depth of genomics studies across a range of cancers, it is now apparent that t...
Alterations in homeostatic functions such as energy balance and sleep patterns are frequently seen in the elderly and these changes may precede and predict subsequent cognitive decline. ...
DATE: January 31, 2017TIME: 10:00am PT/1:00pm ETLearn from renowned clinical expert, Dr. Michael A. Pfaller, as he discusses the critical role of diagnostics and antimicrobial stewardsh...
Breast cancer is a complex heterogeneous disease, with each subtype characterized by distinct clinical features and molecular alterations. The heterogeneity of breast cancer has presented mas...
Circulating Tumor Cells (CTCs) have been extensively explored as circulating biomarkers in various cancers. Due to their rarity, heterogeneity and stem cell-like properties, detecting and pro...
Over the last 15 years, human pluripotent stem cell (hPSC) technologies have progressed from academic curiosities into tools with the promise to underpin commerce, leading to real progress in...
Primary immunodeficiencies (PIDs) are a group of more than 250 genetic disorders that disrupt the immune system, resulting in susceptibility to life-threatening infections, autoimmune disease...
DATE: May 25, 2016
TIME: 8am Pacific time, 11am Eastern time, 4pm UK time, 5pm European time, 11pm Beijing time
In this two-part webinar, we will be presenting the following t...
Targeted sequencing assays are increasingly used to identify tumor mutations that guide therapeutic decisions. Interpretation of a cancer variant’s origin and therapeutic impact poses a...
The rapid implementation of next generation sequencing is changing how genetics and genomics are applied in a clinical setting. However, the quickly evolving technology can be challenging to...
Cancer remains the second leading cause of death in the United States. Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival. Ident...
Recent advances in next-generation sequencing (NGS) have helped to accelerate the pace of discovery in the field of genetic disease research and testing. The ability to analyze multiple genes...
This presentation will discuss variables in rodent colony management that can affect colony breeding efficiency, rodent health, and factors that can modulate rodent models of disease. V...
DNASTAR offers an integrated suite of software for accurate assembly, alignment, and analysis of sequence data from all major next-generation sequencing platforms, supporting key workflows in...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...
Germline cancer genetics became a reality with the cloning of the tumor suppressor gene RB1 for hereditary retinoblastoma in 1986 by Friend and Weinberg. The existence of cancer susceptibili...
With current NGS platforms, the boundaries of variant detection and gene content for genetic disease panels has been vastly expanded leading to increases in detection rates. However these pla...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
DNASTAR offers an integrated suite of software for accurate assembly and analysis of sequence data from all major next-generation sequencing platforms supporting key workflows including targe...
Addressing the antibody reproducibility crisis: A panel discussion with key scientific leaders Reproducibility and antibody validation standards are two significant challenges f...
EVENT DETAILS:DATE: May 16, 2017TIME: 9:00am PT, Noon ETThermo Fisher Scientific is proud to present the SyncD3 webinar series. As a thought-leader in science our first commit...
DATE: May 9, 2017TIME: 8:00am PT, 11:00am ETHearing loss is the most common sensory defect in humans. It affects 360 million people worldwide and by 2020, that number is predi...
DATE: April 26, 2017TIME: 9:00AM PT, 12:00PM ETBiopsies from non-small cell lung cancer (NSCLC) and colorectal adenocarcinoma generally produce small, heterogeneous samples with li...
DATE: April 20th, 2017TIME: 10:00AM SGT, 11:00AM KST, 12:00PM AEST, 2:00PM NZSTWith increasing breadth and depth of genomics studies across a range of cancers, it is now apparent that t...
Alterations in homeostatic functions such as energy balance and sleep patterns are frequently seen in the elderly and these changes may precede and predict subsequent cognitive decline. ...
DATE: January 31, 2017TIME: 10:00am PT/1:00pm ETLearn from renowned clinical expert, Dr. Michael A. Pfaller, as he discusses the critical role of diagnostics and antimicrobial stewardsh...
Breast cancer is a complex heterogeneous disease, with each subtype characterized by distinct clinical features and molecular alterations. The heterogeneity of breast cancer has presented mas...
Circulating Tumor Cells (CTCs) have been extensively explored as circulating biomarkers in various cancers. Due to their rarity, heterogeneity and stem cell-like properties, detecting and pro...
Over the last 15 years, human pluripotent stem cell (hPSC) technologies have progressed from academic curiosities into tools with the promise to underpin commerce, leading to real progress in...
Primary immunodeficiencies (PIDs) are a group of more than 250 genetic disorders that disrupt the immune system, resulting in susceptibility to life-threatening infections, autoimmune disease...
DATE: May 25, 2016
TIME: 8am Pacific time, 11am Eastern time, 4pm UK time, 5pm European time, 11pm Beijing time
In this two-part webinar, we will be presenting the following t...
Targeted sequencing assays are increasingly used to identify tumor mutations that guide therapeutic decisions. Interpretation of a cancer variant’s origin and therapeutic impact poses a...
The rapid implementation of next generation sequencing is changing how genetics and genomics are applied in a clinical setting. However, the quickly evolving technology can be challenging to...
Cancer remains the second leading cause of death in the United States. Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival. Ident...
Recent advances in next-generation sequencing (NGS) have helped to accelerate the pace of discovery in the field of genetic disease research and testing. The ability to analyze multiple genes...
This presentation will discuss variables in rodent colony management that can affect colony breeding efficiency, rodent health, and factors that can modulate rodent models of disease. V...
DNASTAR offers an integrated suite of software for accurate assembly, alignment, and analysis of sequence data from all major next-generation sequencing platforms, supporting key workflows in...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...
Germline cancer genetics became a reality with the cloning of the tumor suppressor gene RB1 for hereditary retinoblastoma in 1986 by Friend and Weinberg. The existence of cancer susceptibili...
With current NGS platforms, the boundaries of variant detection and gene content for genetic disease panels has been vastly expanded leading to increases in detection rates. However these pla...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
DNASTAR offers an integrated suite of software for accurate assembly and analysis of sequence data from all major next-generation sequencing platforms supporting key workflows including targe...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
